Jazz Pharmaceuticals Plc Given “Buy” Rating at Lazard Capital Markets (JAZZ)
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by investment analysts at Lazard Capital Markets in a note issued to investors on Friday, Analyst Ratings.Net reports. They currently have a $93.00 target price on the stock. Lazard Capital Markets’ price objective indicates a potential upside of 6.49% from the company’s current price.
JAZZ has been the subject of a number of other recent research reports. Analysts at UBS AG raised their price target on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) to $98.00 in a research note to investors on Friday. Separately, analysts at R. F. Lafferty initiated coverage on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) in a research note to investors on Thursday, August 22nd. They set a “buy” rating and a $102.00 price target on the stock. Finally, analysts at JMP Securities raised their price target on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) from $66.00 to $74.00 in a research note to investors on Wednesday, August 7th.
Eleven research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus price target of $85.14.
Shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 0.39% during mid-day trading on Friday, hitting $86.99. 180,770 shares of the company’s stock traded hands. Jazz Pharmaceuticals Plc has a 52 week low of $47.37 and a 52 week high of $89.00. The stock has a 50-day moving average of $82.07 and a 200-day moving average of $67.11. The company has a market cap of $5.059 billion and a price-to-earnings ratio of 16.75.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last released its earnings data on Tuesday, August 6th. The company reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by $0.09. The company had revenue of $208.30 million for the quarter, compared to the consensus estimate of $208.71 million. During the same quarter in the previous year, the company posted $1.09 earnings per share. The company’s revenue for the quarter was up 67.7% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals Plc will post $6.30 EPS for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.